We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+199.34%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$404M
AUM Growth
+$265M
Cap. Flow
+$92M
Cap. Flow %
22.79%
Top 10 Hldgs %
66.28%
Holding
52
New
21
Increased
12
Reduced
5
Closed
14

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$11.7M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$8.58M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$7.8M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.11M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.05M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$6.16M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$5.49M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$5.03M
4
VCYT icon
Veracyte
VCYT
+$2.7M
5
ARGX icon
argenx
ARGX
+$2.56M

Sector Composition

Rank Sector Weight
1 Healthcare 83.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
1
Axsome Therapeutics
AXSM
$10.9B
$62.8M 15.55%
607,500
+85,000
+16% +$3.43M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$47.6M 11.78%
500,000
+350,000
+233% +$30.3M
ARWR icon
3
Arrowhead Research
ARWR
$12.1B
$28.1M 6.95%
442,500
+55,000
+14% +$2.73M
KDMN
4
DELISTED
Kadmon Holdings, Inc.
KDMN
$27.4M 6.78%
6,040,000
-372,500
-6% -$1.36M
AUPH icon
5
Aurinia Pharmaceuticals
AUPH
$1.87B
$21.4M 5.31%
1,057,500
+207,500
+24% +$1.91M
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$20.1M 4.99%
+587,089
New +$7.05M
IOVA icon
7
Iovance Biotherapeutics
IOVA
$1.93B
$18.2M 4.5%
656,500
-71,000
-10% -$1.61M
ADVM
8
DELISTED
Adverum Biotechnologies
ADVM
$15.2M 3.77%
+132,250
New +$11.7M
ARVN icon
9
Arvinas
ARVN
$520M
$14.6M 3.62%
356,000
-210,500
-37% -$6.16M
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
$12.3M 3.04%
+1,625,000
New +$8.58M
XENE icon
11
Xenon Pharmaceuticals
XENE
$6.02B
$12M 2.98%
917,500
+215,000
+31% +$2.26M
KPTI icon
12
Karyopharm Therapeutics
KPTI
$44.6M
$11.3M 2.8%
39,333
+23,500
+148% +$5.1M
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.24B
$9.75M 2.41%
+2,825,000
New +$7.11M
CNST
14
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$9.3M 2.3%
+197,500
New +$5.7M
DRNA
15
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$8.54M 2.11%
+387,500
New +$7.8M
MIST icon
16
Milestone Pharmaceuticals
MIST
$139M
$8.14M 2.02%
508,500
+139,000
+38% +$2.46M
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.81M 1.93%
+910,000
New +$3.25M
RETA
18
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$7.77M 1.92%
38,000
-7,000
-16% -$1.28M
BLU
19
DELISTED
BELLUS Health Inc.
BLU
$6.16M 1.52%
810,000
+25,000
+3% +$171K
APLS
20
DELISTED
Apellis Pharmaceuticals
APLS
$5.74M 1.42%
+187,500
New +$5.19M
RNAC icon
21
Cartesian Therapeutics
RNAC
$231M
$5.34M 1.32%
+78,807
New +$3.8M
NGNE icon
22
Neurogene
NGNE
$656M
$4.59M 1.14%
+18,625
New +$1.86M
KRTX
23
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$4.22M 1.04%
+56,000
New +$2.45M
APLT
24
DELISTED
Applied Therapeutics
APLT
$4.04M 1%
148,000
+65,000
+78% +$1.11M
INSM icon
25
Insmed
INSM
$21.3B
$4.04M 1%
169,000
-51,000
-23% -$1.04M
1
2 3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Acuta Capital Partners held 52 positions worth $404M, up 191% from $139M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Acuta Capital Partners deployed $92M of net new capital in Q4 2019, opening 21 new positions and adding to 12 existing holdings. Its largest new stake was Adverum Biotechnologies: 132,250 shares worth $15.2M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Arvinas, an estimated $6.16M trimmed.

  • Acuta Capital Partners's largest Q4 2019 buy was Adverum Biotechnologies: 132,250 shares worth $15.2M.
  • Acuta Capital Partners added most to Karyopharm Therapeutics in Q4 2019, an estimated $5.1M increase.
  • Acuta Capital Partners's biggest Q4 2019 reduction was Arvinas, cutting an estimated $6.16M.
  • Acuta Capital Partners fully exited CRISPR Therapeutics in Q4 2019, selling an estimated $5.49M.
  • Acuta Capital Partners's ten largest holdings make up 66% of its $404M portfolio in Q4 2019.
  • Acuta Capital Partners opened 21 new positions and closed 14 in Q4 2019.
  • Acuta Capital Partners's portfolio value rose 191% quarter-over-quarter to $404M.

Based on Acuta Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.